Yuhua Feng

Dr. Yuhua Feng


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2024 in Heliyon
Verified
Journal Article
Open access
NZNa Zhang
Na Zhang
THTao Hou
Tao Hou
SZSujuan Zhang
Sujuan Zhang
JLJie Ling
Jie Ling
SJShun Jiang
Shun Jiang
YFYuhua Feng
Yuhua Feng
Blood-based immune-inflammation indexes have been widely used to predict survival in a variety of cancers. In this research, we seeked to evaluate a novel immune-inflammation marker, named the pan-immune-inflammation value (PIV), in patients with nasopharyngeal carcinoma (NPC) undergoing definitive radiotherapy. A group of 377 patients with NPC was retrospectived analyzed. Clinical data and laboratory data were collected. Receiver operating characteristic (ROC) curve analysis was performed in order to determine the optimal PIV cut-off value. Survival curves were estimated by Kaplan-Meier method, and prognostic variables were identified using a Cox regression model. Additionally, we developed a nomogram and assessed its acuracy using the concordance index (C-index) and a calibration curve. The optimal PIV cut-off value was 146.24 according to ROC analysis. High PIV was related to poorer Eastern Cooperative Oncology Group Performance Status (ECOG PS) score (p = 0.017), more advanced T (p<0.001) and clinical stages (p = 0.024). In univariate analysis, older Age, poorer ECOG PS, higher Epstein–Barr virus DNA (EBV-DNA), advanced T, N and clinical stage, and higher PIV levels were related to patients' poorer overall survival (OS). Poorer ECOG PS, higher EBV-DNA, later T stage, later clinical stage, and higher PIV were associated with patients' poorer progression free survival (PFS). Male sex and later T stage were associated with patients' poorer locoregional recurrence free survival (LRRFS). Poorer ECOG PS, higher EBV-DNA, later T stage, later clinical stage, and higher PIV were associated with patients’ poorer distant metastasis free survival (DMFS). Multivariate analysis demonstrated that PIV was an independent prognostic index for OS (HR 2.231, 95 % CI 1.241–4.011, P = 0.007), PFS (HR 1.664, 95 % CI 1.003–2.760, P = 0.049), and DMFS(HR 2.081, 95 % CI 1.071–4.044, P = 0.031). Nomogram C-indexes for the nomogram of OS were 0.684, and PFS were 0.62, respectively. Survival predictions and actual survival were consistent according to the calibration curve. Pre-treatment PIV is a promising biomarker for predicting survival in patients with NPC.

1 June 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RZRuolan Zeng
Ruolan Zeng
YTYouhong Tang
Youhong Tang
HZHui Zhou
Hui Zhou
YLYiping Liu
Yiping Liu
JHJunhui Huang
Junhui Huang
MZMeizuo Zhong
Meizuo Zhong

1 November 2019 in Translational Oncology
Verified
Journal Article
Open access
JLJieqiong Liu
Jieqiong Liu
MZMeizuo Zhong
Meizuo Zhong
YFYuhua Feng
Yuhua Feng
SZShan Zeng
Shan Zeng
YWYikai Wang
Yikai Wang
HZHui Zhou
Hui Zhou
Seventy percent of intrahepatic cholangiocarcinoma (ICC) patients are inoperable. Treatment for unresectable patients is essential to improve poor survival. We aimed to evaluate the prognostic factors for ICC patients, and investigate the potential treatment strategies for unresectable patients. ICC patients were identified in SEER registry in 2004-2013. Univariate and multivariate Cox proportional hazard regression analysis were performed to evaluate the effect of treatment strategies. Of 2248 cases diagnosed in 2010-2013 and staged according to the American Joint Committee on Cancer (AJCC) 7th edition, 1706 (76.13%) did not receive cancer-directed surgery. This portion increased compared to those diagnosed between 2004 and 2009 and staged according to the AJCC 6th edition (72.87%). In addition, the percentage of stage 4 cases increased, while stage 3 cases decreased, because AJCC 7th staging system categorized both T4 and N1 patients into stage IV, which were previously categorized into stage III by AJCC 6th staging system. Patients with radiofrequency ablation (RFA) showed a poorer survival in 2004-2009 (P = .0213), but an almost the same survival as patients with tumor resection in 2010-2013 (P = .51), suggesting that RFA performed better in recent years. Lymphadenectomy showed protective effect for unresectable patients. Radiotherapy improved cancer-specific survival in non-surgery patients (P < .0001).The proportion of stage IV patients increased tremendously from 37.4% in 2004-2009 to 58.7% in 2010-2013. Among 1319 stage IV patients (2010-2013), surgery at distant metastatic sites improved cancer-specific survival. For unresectable tumors, RFA, radiotherapy, lymphadenectomy, and surgery of distant metastases showed significant benefits to improve cancer-specific survival.

28 December 2024
Verified
Journal Article
Open access
CDChao Deng
Chao Deng
ZCZui Chen
Zui Chen
JLJie Ling
Jie Ling
YXYangchun Xie
Yangchun Xie
XZXiayan Zhao
Xiayan Zhao
THTao Hou
Tao Hou
Peripheral whole blood cell counts have been used as prognostic indicators for various cancers, but their predictive value in nasopharyngeal carcinoma remain unclear. This study aims to evaluate the prognostic significance of the pretreatment hemoglobin×lymphocyte/monocyte ratio (HLMR) in non-recurrent, non-metastatic NPC patients undergoing definitive radiotherapy. Clinical and follow-up data from 805 NPC patients who completed definitive radiotherapy or chemoradiotherapy were retrospectively analyzed. Pretreatment hemoglobin, lymphocyte count, and monocyte count were collected to calculate HLMR. Receiver operating characteristic (ROC) curves were used to determine the optimal cut-off value of HLMR. Patients were then classified into high and low HLMR groups. The association between HLMR and clinicopathological characteristic was assessed using chi-square tests. Independent prognostic factors for overall survival (OS) and progression-free survival (PFS) were identified using Cox proportional hazards models. A nomogram was constructed based on the independent predictors to estimate patient survival rates, and internal validation was performed using a validation cohort. The ROC curve identified 605.5 as the optimal HLMR cut-off value for predicting 5-year survival. Multivariate Cox regression analysis revealed that T stage (HR=1.886, 95% CI 1.331 to 2.673, P<0.001), N stage (HR=2.021, 95% CI 1.267 to 3.225, P=0.003), Eastern Cooperative Oncology Group (ECOG) score (HR=3.991, 95% CI 1.257 to 12.677, P=0.019), concurrent chemoradiotherapy regimen (HR=0.338, 95% CI 0.156 to 0.731, P=0.006), and HLMR (HR=0.648, 95% CI 0.460 to 0.912, P=0.013) were independent prognostic factors for OS. A nomogram including T stage, N stage, and HLMR in the training cohort was constructed to predict 3-, 5-, and 7-year OS, with a C-index of 0.713. The area under the curves for predicting 3-, 5-, and 7-year OS were 0.744, 0.665, and 0.682, respectively. Calibration curves showed good agreement between predicted and observed survival rates. The above results were further confirmed in the validation cohort. Pretreatment HLMR may serve as a promising prognostic biomarker for patients with nasopharyngeal carcinoma.

17 May 2022 in Research Square
Verified
Preprint
Open access
PDF file
YFYuhua Feng
Yuhua Feng
LWLeyuan Wang
Leyuan Wang
YYYan Yu
Yan Yu
LYLiangchun Yang
Liangchun Yang
Background: Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm, immune system dysfunction may attribute to the cause of LCH. There is no standard prognosis evaluation system for LCH in children. We investigated the prognosis predictive value of peripheral lymphocyte subsets in childhood LCH patients.Methods: A cohort of 79 childhood LCH patients was retrospectively studied. The prognosis predictive significance of CD3+ T cells, CD3+CD4+ T cells, CD3+CD8+ T cells, NK cells, B cells and CD4/CD8 ratio were analyzed.Results: After 6-week induction therapy, the percentage of CD3+ T cells, CD3+CD4+ T cells and CD4/CD8 ratio were significantly increased, while CD3+CD8+ T cells and B cells were decreased. CD3+CD8+ T cells and B cells were closely related to BRAF V600E and MAP2K1 mutation. ∆CD3+ T cells, ∆CD3+CD4+ T cells, ∆CD3+CD8+ T cells, ∆NK cells and ∆B cells were related to treatment efficacy. As for organ involvements, ∆CD3+ T cells and ∆CD3+CD8+ T cells were related to liver involvement, ∆CD4/CD8 ratio was related to CNS involvement ∆CD3+ T cells and ∆B cells were related to BRAF V600E mutation, while ∆CD3+CD4+ T cells was related to MAP2K1 mutation. Furthermore, increased ∆CD3+ T cells, decreased ∆CD3+CD4+ T cells, decreased ∆CD3+CD8+ T cells, decreased ∆NK cells and increased ∆B cells were predictors for superior PFS, while increased ∆CD3+ T cells, decreased ∆CD3+CD8+ T cells and decreased ∆NK cells were predictors for superior OS. In addition, multivariate Cox regression analysis showed that ∆CD3+ T cells and ∆CD3+CD8+ T cells were independent prognostic factors for PFS.Conclusions: The peripheral lymphocyte subsets including CD3+ T cells, CD3+CD4+ T cells, CD3+CD8+ T cells, NK cells and B cells might be promising predictive indicators for LCH in children.